Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark's continuing relevance to the company, and Genmab's value proposition for the next generation of talent.
Genmab has strong, focused investment into its pipeline and capabilities and is now transitioning into a fully-integrated commercial company. We have made lots of progress, but this is only the beginning
